Vectibix (panitumumab)

Adagrasib monotherapy yielded a median PFS of 4.4-5.6 months, an OS of 10-19.8 months, and an ORR of 19-23%, while its combination with cetuximab reported a PFS of 6.9 months, an OS of 13.4-15.9 months and an ORR of 34-46%...When combined with panitumumab, 960 mg sotorasib demonstrated better results with a PFS of 5.6-5.7 months, OS of 15.2 months and an ORR of 12.5-30%. Similarly, divarasib monotherapy led to a PFS of 5.6-6.9 months and an ORR of 20%, while its combination with cetuximab resulted in a PFS of 8.1 months and an ORR of 62.5%. Combination therapy of olomorasib and MK-1084, which are new-generation KRAS p.G12C (c.34G > T) inhibitors, with cetuximab also demonstrated highly promising efficacy with ORR of 38-44% and 50%, respectively...Initial results of KRAS-G12C inhibitors appear highly promising when they are combined with anti-EGFR therapy compared to historical therapeutic agents indicated for patients with chemotherapy-refractory CRC. Encouraging benefits warrant frontline trials with these novel therapeutics.

As a first-line treatment for patients with left-sided all RAS or KRAS wild-type mCRC, panitumumab plus doublet chemotherapy may be suggested better efficacy outcomes than cetuximab plus doublet chemotherapy.

Multiplexed biomarker integration (electrochemical EGFR) quantification with concomitant ctDNA detection, extracellular vesicle (EV) proteomic characterization, and serum biomarker detection (carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), micro ribonucleic acid (miRNA) signatures) provides comprehensive tumor phenotyping, enabling patient stratification for cetuximab or panitumumab monoclonal antibody therapy with a reported 76.9% diagnostic accuracy in predicting therapeutic response. Systemic clinical implementation requires multicenter prospective comparative studies, regulatory approval (Food and Drug Administration (FDA) 510(k)/de novo; Conformité Européenne (CE) marking), and point-of-care deployment in community oncology facilities and healthcare environments with constrained resources. Electrochemical EGFR biomarking is a clinically practicable analytical platform for advancing precision oncology using accessible, quantitatively precise multiplex biomarkers that can be used across a wide range of healthcare systems.

P3, N=94, Recruiting, SWOG Cancer Research Network | Not yet recruiting --> Recruiting

P1/2, N=6, Not yet recruiting, Amgen Inc.

P1/2, N=30, Recruiting, Stanford University | Trial completion date: Feb 2027 --> Sep 2026 | Trial primary completion date: Jan 2026 --> Sep 2026

P1/2, N=46, Recruiting, Stanford University | Trial completion date: Dec 2025 --> May 2026 | Trial primary completion date: Dec 2025 --> May 2026

P3, N=160, Active, not recruiting, Amgen | Trial completion date: Jan 2026 --> May 2026

These findings support the use of anti-EGFR rechallenge strategy aslater-line treatment when tumor shrinkage is a clinical priority. Further evidence from prospective trials is required.

P2, N=16, Active, not recruiting, Nicholas DeVito, MD | Recruiting --> Active, not recruiting

P1, N=434, Recruiting, Amgen | Trial completion date: Oct 2030 --> Apr 2031 | Trial primary completion date: Oct 2027 --> Apr 2028

P2, N=214, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Trial completion date: Dec 2025 --> Mar 2026